SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--FLX Bio, Inc., a biopharmaceutical company focused on the discovery and
development of oral small-molecule drugs to activate the immune system,
today announced the appointment of two leading oncology experts to its
scientific advisory board (SAB). Drew Pardoll, M.D., Ph.D., of Johns
Hopkins University, School of Medicine and Philip Greenberg, M.D., of
the Fred Hutchinson Cancer Research Center and University of Washington,
join Jeff Bluestone, Ph.D., David Goeddel, Ph.D., Antoni Ribas, M.D.,
Ph.D., Alexander Rudensky, Ph.D. and Robert Zamboni, Ph.D., bringing the
total SAB to seven key opinion leaders in immunotherapy.

“Drs. Pardoll and Greenberg have been pioneering the field of
immuno-oncology for several decades, and continue to be at the forefront
of discovery, bringing rich and relevant experience in immunotherapies
targeting T cell discovery and development,” said Brian R. Wong, M.D.,
Ph.D., CEO of FLX Bio. “As we prepare to enter the clinic with our lead
immunotherapy, an oral small molecule targeting the CCR4 receptor on
regulatory T cells, we are extremely pleased to attract the scientific
experts driving this field forward to inform our cancer pipeline
decisions and advancements.”

Dr. Pardoll serves as the Abeloff Professor of Oncology, Medicine,
Pathology and Molecular Biology and Genetics at the Johns Hopkins
University, School of Medicine, director of the Bloomberg-Kimmel
Institute for Cancer Immunotherapy and co-director of the Cancer
Immunology Program at the Sidney Kimmel Comprehensive Cancer Center at
Johns Hopkins. He has made a number of basic advances in cellular
immunology, including the discovery of gamma - delta T cells, NKT cells
and interferon-producing killer dendritic cells. Over the past two
decades, Dr. Pardoll has studied molecular aspects of dendritic cell
biology and immune regulation, particularly related to mechanisms by
which cancer cells evade elimination by the immune system. He is an
inventor of numerous immunotherapies and discovered key members of
several immunology pathways including one of the two PD-1 checkpoint
inhibitor ligands. He received his M.D., Ph.D., from Johns Hopkins
University and is an author on over 300 papers as well as over 20 book
chapters regarding T cell immunology and cancer vaccines. He has served
on the editorial board of the Journal of the National Cancer
Institute and Cancer Cell, and has served as a
member of scientific advisory boards for numerous academic institutions
and biotechnologies.

Dr. Greenberg serves as the head of the Program in Immunology at the
Fred Hutchinson Cancer Research Center as well as professor in both the
Oncology and Immunology divisions of the University of Washington,
Department of Medicine. Dr. Greenberg’s research focuses on both basic
immunology and cancer immunobiology to treat human malignancies and
chronic infections, with a particular expertise in using T cells to
selectively target disease. He has been elected to several honorary
societies including the American Society of Clinical Investigation, the
American Association of Physicians, the American Association for the
Advancement of Science, and the American College of Physicians, and has
received two National Institutes of Health Method to Extend Research in
Time awards as well as the International Society for Immunotherapy of
Cancer (SITC) Team Science Award for Career Achievements and Cancer
Research Institute’s William B. Coley Award for Distinguished Research
in Tumor Immunology. He received his B.S. degree in Biology from
Washington University and his M.D. summa cum laude from the State
University of New York, Downstate Medical Center.

About FLX Bio

FLX Bio, Inc. is a cancer immunotherapy company focused on the discovery
and development of orally-available, small molecule drugs to activate
the immune system and eradicate cancer. Using its integrated
immuno-oncology drug discovery platform, FLX Bio’s small molecule
compounds specifically target proteins and pathways that selectively
inhibit regulatory T cells and myeloid cells within the tumor
microenvironment. Its lead candidate, a best-in-class CCR4 inhibitor,
has the potential to be used alone or in combination with checkpoint
inhibitors to treat a variety of cancers, and is expected to enter the
clinic in 2017.

Located in South San Francisco, Calif., and funded by leading investors,
including Kleiner Perkins Caufield & Byers (KPCB), The Column Group
(TCG), Topspin Partners and Celgene, FLX Bio has assembled a leadership
team and advisory group with a proven track record of success and team
of scientists with substantial knowledge and expertise in drug
discovery and translational areas essential to execute on this approach.
For more information, please visit www.flxbio.com.